scholarly journals Daptomycin Susceptibility of Unusual Gram-Positive Bacteria: Comparison of Results Obtained by the Etest and the Broth Microdilution Method

2007 ◽  
Vol 51 (4) ◽  
pp. 1570-1572 ◽  
Author(s):  
Yu-Tsung Huang ◽  
Chun-Hsing Liao ◽  
Lee-Jeng Teng ◽  
Po-Ren Hsueh
Keyword(s):  
Listeria Monocytogenes ◽  
Broth Microdilution ◽  
Gram Positive ◽  
Gram Positive Bacteria ◽  
Comparison Of Results ◽  
Microdilution Method ◽  
Broth Microdilution Method

ABSTRACT MICs of daptomycin, linezolid, and vancomycin against 212 isolates, including Listeria monocytogenes and Pediococcus, Leuconostoc, Rhodococcus, and Nocardia spp., were determined by the broth microdilution method; daptomycin MICs were also determined by the Etest. Except with those for Leuconostoc spp., daptomycin Etest MICs showed >90% agreement with MICs obtained by the broth microdilution method.

scholarly journals In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017

2019 ◽  
Vol 64 (3) ◽  
Author(s):  
Ian Morrissey ◽  
Stephen Hawser ◽  
Sibylle H. Lob ◽  
James A. Karlowsky ◽  
Matteo Bassetti ◽  
...  
Keyword(s):  
Antimicrobial Agents ◽  
Clinical Isolates ◽  
Gram Positive ◽  
Content Type ◽  
Gram Positive Bacteria ◽  
Microdilution Method ◽  
Clinical Laboratories ◽  
Broth Microdilution Method ◽  
Doubling Dilution

ABSTRACT Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by resistant Gram-positive pathogens. Here, we evaluated the in vitro activities of eravacycline and comparator antimicrobial agents against a recent global collection of frequently encountered clinical isolates of Gram-positive bacteria. The CLSI broth microdilution method was used to determine in vitro MIC data for isolates of Enterococcus spp. (n = 2,807), Staphylococcus spp. (n = 4,331), and Streptococcus spp. (n = 3,373) isolated primarily from respiratory, intra-abdominal, urinary, and skin specimens by clinical laboratories in 37 countries on three continents from 2013 to 2017. Susceptibilities were interpreted using both CLSI and EUCAST breakpoints. There were no substantive differences (a >1-doubling-dilution increase or decrease) in eravacycline MIC90 values for different species/organism groups over time or by region. Eravacycline showed MIC50 and MIC90 results of 0.06 and 0.12 μg/ml, respectively, when tested against Staphylococcus aureus, regardless of methicillin susceptibility. The MIC90 values of eravacycline for Staphylococcus epidermidis and Staphylococcus haemolyticus were equal (0.5 μg/ml). The eravacycline MIC90s for Enterococcus faecalis and Enterococcus faecium were 0.06 μg/ml and were within 1 doubling dilution regardless of the vancomycin susceptibility profile. Eravacycline exhibited MIC90 results of ≤0.06 μg/ml when tested against Streptococcus pneumoniae and beta-hemolytic and viridans group streptococcal isolates. In this surveillance study, eravacycline demonstrated potent in vitro activity against frequently isolated clinical isolates of Gram-positive bacteria (Enterococcus, Staphylococcus, and Streptococcus spp.), including isolates collected over a 5-year period (2013 to 2017), underscoring its potential benefit in the treatment of infections caused by common Gram-positive pathogens.

scholarly journals Antibacterial Triterpenoids from the Bark of Sonneratia alba (Lythraceae)

2015 ◽  
Vol 10 (2) ◽  
pp. 1934578X1501000
Author(s):  
Harizon ◽  
Betry Pujiastuti ◽  
Dikdik Kurnia ◽  
Dadan Sumiarsa ◽  
Yoshihito Shiono ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Antibacterial Activity ◽  
Mass Spectrometric ◽  
Broth Microdilution ◽  
Mass Spectrometric Data ◽  
Spectrometric Data ◽  
Gram Positive Bacteria ◽  
Microdilution Method ◽  
Sonneratia Alba ◽  
Broth Microdilution Method

The new lupane-type triterpenoid, 3β-hydroxy-lup-9(11), 12-diene, 28-oic acid (1), along with two known lupane-type triterpenoids, lupeol (2) and lupan-3p-ol (3), were isolated from the bark of Sonnetaria alba. The structure of the new compound was elucidated on the basis of spectroscopic and mass spectrometric data analysis. Using the broth microdilution method, all compounds exhibited antibacterial activity against the Gram-positive bacteria Staphylococcus aureus ATCC 6538 and Streptococcus mutans ATCC 25175, with minimum inhibitory concentrations ranging from 15-33 to 35-55 ng/mL, respectively.

scholarly journals In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.

1996 ◽  
Vol 40 (9) ◽  
pp. 2142-2146 ◽  
Author(s):  
K V Singh ◽  
T M Coque ◽  
B E Murray
Keyword(s):  
Staphylococcus Aureus ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Positive Bacteria ◽  
Microdilution Method ◽  
Broth Microdilution Method ◽  
Gentamicin Resistance ◽  
High Level

The in vitro activity of the trinem sanfetrinem (formerly GV104326) (GV) was compared with that of vancomycin, ampicillin, and/or nafcillin against 287 gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and multiresistant enterococci, by the agar and microbroth dilution methods. GV demonstrated 2 to 16 times more activity than ampicillin and nafcillin against the majority of these organisms. The MIC range of GV was 16 to 64 micrograms/ml for 19 Enterococcus faecium strains that were highly resistant to ampicillin (ampicillin MIC range, 64 to 512 micrograms/ml) and vancomycin resistant and 0.25 to 32 micrograms/ml for resistant Rhodococcus spp. Similar activities (+/-1 dilution) were observed by either the agar or the broth microdilution method. GV demonstrated bactericidal activity against a beta-lactamase-producing Enterococcus faecalis strain and against two methicillin-susceptible Staphylococcus aureus strains in 10(5)-CFU/ml inocula. Synergy between GV and gentamicin was observed against an E. faecalis strain that lacked high-level gentamicin resistance. The activity of GV suggests this compound warrants further study.

Antimicrobial Essential Oil Combinations to Combat Foot Odour

Planta Medica ◽  
2018 ◽  
Vol 84 (09/10) ◽  
pp. 662-673 ◽  
Author(s):  
Ané Orchard ◽  
Alvaro Viljoen ◽  
Sandy van Vuuren
Keyword(s):  
Antimicrobial Activity ◽  
Essential Oil ◽  
Essential Oils ◽  
Antimicrobial Efficacy ◽  
Juniperus Virginiana ◽  
Broth Microdilution ◽  
Synergistic Interactions ◽  
Microdilution Method ◽  
Broth Microdilution Method

AbstractFoot odour (bromodosis) is an embarrassing and perplexing condition mostly caused by bacteria of the Brevibacterium species. Essential oils are a credible option as an affordable treatment of odour and contribute towards antimicrobial efficacy. Therefore, this study sets out to investigate the antimicrobial activity of essential oil combinations against odour-causing bacteria. The broth microdilution method was used to investigate the antimicrobial activity of 119 essential oil combinations, and the fractional inhibitory index was calculated to determine the interactive profile. Combinations that resulted in synergy in 1 : 1 ratios were further evaluated in different concentrations, and isobolograms were plotted to determine the influence of the ratio on overall activity. Numerous combinations could be identified as having synergistic interactions against the Brevibacterium spp. and no antagonism was observed. The combination of Juniperus virginiana (juniper) and Styrax benzoin (benzoin) demonstrated synergy against all three Brevibacterium spp. tested and J. virginiana was the essential oil responsible for the majority of the synergistic interactions. The results reported here confirm the promising potential of the majority of these oils and selected combinations in treating and controlling bromodosis.

scholarly journals Standartization of broth microdilution method for Mycobacterium tuberculosis

2000 ◽  
Vol 95 (1) ◽  
pp. 127-129 ◽  
Author(s):  
Clarice Queico Fujimura Leite ◽  
Ana Laura Remédio Zeni Beretta ◽  
Ivone Shizuko Anno ◽  
Maria Alice da Silva Telles
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Broth Microdilution ◽  
Microdilution Method ◽  
Broth Microdilution Method

scholarly journals Corrigendum

2017 ◽  
Vol 4 (6) ◽  
pp. 193-193
Keyword(s):  
United States ◽  
The United States ◽  
Original Text ◽  
The European Union ◽  
Broth Microdilution ◽  
Alternative Treatments ◽  
Gram Positive ◽  
Baseline Activity ◽  
Broth Microdilution Method ◽  
Complicated Skin

Das B, Sarkar C, Das D et al. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis. 2017 Mar; 4(2): 49–73. DOI: 10.1177/2049936117690501 The authors wish to highlight the following corrections, which should have appeared in the original text: 1.  Page 49, Abstract, lines 4–5: Telavancin is approved for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in the United States when alternative treatments are not available. In Russia and Canada, telavancin is approved for both complicated skin and skin-structure infections (cSSSI) and HABP/VABP. 2.  Page 50, right panel, para 2, lines 15–18: Revised per telavancin label based on latest PI and EMA (also pasted below). In the United States, telavancin is approved in adults for the treatment of cSSSI due to susceptible Gram-positive pathogens. In addition, telavancin is approved for HABP/VABP when alternative treatments are not suitable. In Canada and Russia, telavancin is approved for Gram-positive pathogens for the treatment of patients with cSSSI and HABP/VABP. In the European Union, telavancin is approved for the treatment of nosocomial pneumonia, known or believed to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternative medicines are unsuitable. 3.  Page 51, right panel, para 1, lines 1–6: Per the latest (2016) telavancin PI, HABP/VABP indication for telavancin should be included. 4.  Page 51, Figure 1 caption: The hydrophilic nature of telavancin contributes to its half-life. 5.  Page 53, left panel, para “In vitro activity”, lines 5–8: As per the following (newer) article, which states that “Telavancin MIC is 16-32 fold lower than vancomycin against MRSA.” Mendes RE, Flamm RK, Farrell DJ, et al. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. J Chemother 2015; 28: 83–88. DOI: 10.1179/1973947815Y.0000000050 6.  Page 53, right panel, para 1, lines 11–16: Per the Mendes et al. (2015) article listed above, telavancin minimum inhibitory concentration (MIC) is 16- to 32-fold lower than vancomycin against MRSA. 7.  Page 54, Table 1: These MIC values were estimated using old methods. Revise the MIC values based on the references for new MIC methods (see below). Farrell DJ, Mendes RE, Rhomberg PR, et al. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother 2014; 58(9): 5547–5551. DOI: 10.1128/AAC.03172-14 8.  Page 61, right panel, para “ATTAIN trials (ATTAIN 1 and 2)”, lines 9–12: The ATTAIN trials did not include patients with “healthcare-associated pneumonia,” therefore, any mention of this is not correct.

scholarly journals In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria

2006 ◽  
Vol 50 (12) ◽  
pp. 4027-4029 ◽  
Author(s):  
Lucio Vera-Cabrera ◽  
Barbara A. Brown-Elliott ◽  
Richard J. Wallace ◽  
Jorge Ocampo-Candiani ◽  
Oliverio Welsh ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Clinical Isolates ◽  
Nontuberculous Mycobacterium ◽  
The Novel ◽  
Broth Microdilution ◽  
Reference Species ◽  
Microdilution Method ◽  
Broth Microdilution Method ◽  
Aerobic Actinomycetes

ABSTRACT DA-7867 and DA-7157 are oxazolidinones active against pathogenic aerobic actinomycetes including Nocardia spp. and Mycobacterium tuberculosis. However, the activity of these drugs against nontuberculous mycobacterium (NTM) species is not known. In this work, we compared the susceptibilities of 122 clinical isolates and 29 reference species of both rapidly growing and slowly growing mycobacteria to linezolid, DA-7867, and DA-7157 by the broth microdilution method. The MICs for 50 and 90% of the strains tested (MIC50s and MIC90s, respectively) of DA-7867 and DA-7157 were lower than those of linezolid. In all of the cases, a MIC90 of <8 μg/ml was observed for all of the species tested in both groups of NTM. For M. kansasii and M. marinum isolates, the MIC90s of both DA-7867 and DA-7157 were less than 0.5 μg/ml. These results demonstrate the potential of these compounds to treat NTM infections.

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods

2021 ◽  
Author(s):  
Xue Ting Tan ◽  
Stephanie Jane Ginsapu ◽  
Fairuz binti Amran ◽  
Salina binti Mohamed Sukur ◽  
Surianti binti Shukor
Keyword(s):  
Filamentous Fungi ◽  
Susceptibility Testing ◽  
Rhizopus Oryzae ◽  
Antifungal Susceptibility ◽  
Sporothrix Schenckii ◽  
Rank Test ◽  
Broth Microdilution ◽  
Syncephalastrum Racemosum ◽  
Microdilution Method ◽  
Broth Microdilution Method

Abstract Background: Voriconazole is a trizaole antifungal to treat fungal infection. In this study, the susceptibility pattern of voriconazole against filamentous fungi was studied using Sensititre® YeastOne and Clinical & Laboratory Standards Institute (CLSI) M38 broth microdilution method. Methods: The suspected cultures of Aspergillus niger, A. flavus, A. fumigatus, A. versicolor, A. sydowii, A. calidoutus, A. creber, A. ochraceopetaliformis, A. tamarii, Fusarium solani, F. longipes, F. falciferus, F. keratoplasticum, Rhizopus oryzae, R. delemar, R. arrhizus, Mucor sp., Poitrasia circinans, Syncephalastrum racemosum and Sporothrix schenckii were received from hospitals. Their identification had been confirmed in our lab and susceptibility tests were performed using Sensititre® YeastOne and CLSI M38 broth microdilution method. The significant differences between two methods were calculated using Wilcoxon Sign Rank test.Results: Mean of the minimum inhibitory concentrations (MIC) for Aspergillus spp. and Fusarium were within 0.25 μg/mL-2.00 μg/mL by two methods except A. calidoutus, F. solani and F. keratoplasticum. Moreover, mean of MIC for S. schenkii were around 3.00 μg/mL by two methods. In contrast, mean of MIC for Rhizopus spp., Mucor sp., P. circinans and S. racemosum were ≥6.00 μg/mL by two methods. Generally, the MIC obtained by Sensititre YeastOne was one two-fold increase or decrease compared with the results obtained by CLSI method. The overall agreement between Sensititre YeastOne and CLSI methods to test susceptibility testing of voricaonazole was more than 70% except A. sydowii. The significant differences between two methods were significant when tested on A. niger, A. flavus, A. fumigatus, A. versicolor, A. sydowii, F. solani and S. schenkii. Conclusions: In conclusion, Sensititre YeastOne method appears to be an alternative procedure for antifungal susceptibility testing for some Malaysian moulds.

Sign in / Sign up

Export Citation Format

Share Document